AGA Nanotech (UK) has been awarded the 2025 EWMA Innovation Competition prize for their groundbreaking Battlestar™ antimicrobial delivery system. This innovative solution demonstrates broad-spectrum efficacy against bacteria, fungi, viruses, and spores — all with zero risk of resistance.
At the EWMA Innovation Forum in Barcelona, CEO Harsha Siani accepted the €10,000 prize on behalf of the company.
Isoherranen Kirsi, President of EWMA, shared: “This prize recognizes solutions with the potential to significantly improve wound care quality and patient outcomes. AGA Nanotech is a well-deserved winner of the 2025 competition.”
Sean Willis, Vice President, Research & Development, Advanced Wound Care at Convatec added: “Many congratulations to the winner, Aga Nanotech, and their novel technology. It’s a highly innovative advancement adding to the crucial development and adoption of new and improved solutions in managing wounds effectively.”
Mitch Sanders, PhD, CEO at ProDevLabs, LLC said “It is crucial to facilitate the development and uptake of new and better solutions into clinical use as wounds are a burden on societies on a level with cancer. AGA Nanotech has developed a solution with the potential for investors and subsequent commercialization.”
🔬 About AGA Nanotech
AGA Nanotech is transforming wound care with Battlestar™, an antimicrobial delivery system that combats biofilms and multidrug-resistant infections while promoting healing. By generating reactive oxygen species (ROS) in situ, Battlestar™ delivers broad-spectrum antimicrobial and antibiofilm activity, without antibiotics.
🔗 Learn more about AGA Nanotech: www.agananotech.com
Convatec sponsored the EWMA Innovation Forum and Innovation Competition. To learn more about the company, visit https://lnkd.in/gpaC3s2E
ProDevLabs, LLC sponsored the EWMA Innovation Forum and Innovation Competition. To learn more about the company, visit https://prodevlabs.com/